Your institution may have access to this item. Find your institution then sign in to continue.
Title
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Authors
Turpie, A G G; Fisher, W D; Bauer, K A; Kwong, L M; Irwin, M W; Kälebo, P; Misselwitz, F; Gent, M; OdiXa-Knee Study Group
Abstract
BAY 59-7939, a novel, oral, direct factor Xa inhibitor, is in clinical development for the prevention of venous thromboembolism (VTE), a frequent complication following orthopaedic surgery.
Publication
Journal of thrombosis and haemostasis : JTH, 2005, Vol 3, Issue 11, p2479